FDA Moves to End Large-Scale GLP-1 Compounding
The FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk list. The public comment window closes June 29, 2026.
May 29, 2026 · 3 min read
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list — the regulatory mechanism that allowed large-scale compounding pharmacies to produce these drugs at scale. The proposal was announced April 30, 2026, and the public comment window is open through June 29, 2026. Industry analysts expect a final rule by Q3 2026.
What the 503B bulks list is and why it matters
503B outsourcing facilities are large-scale compounding operations that can produce drugs in bulk quantities and distribute them to healthcare providers and patients without individual prescriptions. Under FDA rules, 503B facilities can only use bulk drug substances to compound when those substances appear on the 503B bulks list — or when the compounded drug is on the FDA's shortage list at the time of compounding and dispensing.
GLP-1 drugs entered the 503B pathway when Novo Nordisk's semaglutide products (Ozempic, Wegovy) and Eli Lilly's tirzepatide products (Mounjaro, Zepbound) were placed on the FDA shortage list in 2022–2023. That shortage-based authorization ended when the FDA removed semaglutide from the shortage list in February 2025 and tirzepatide supply stabilized earlier that year.
The April 30 proposal concerns the next avenue for large-scale compounding: the 503B bulks list itself. The FDA is now proposing to find no clinical need for outsourcing facilities to compound GLP-1 drugs from bulk substances, which would remove this pathway entirely.
Why the FDA is proposing this now
The FDA's rationale, as reported across multiple trade publications, centers on shortage resolution and safety. With brand-name GLP-1 drugs now widely available — and with 503A compounding pharmacies also facing restrictions after the shortage-based window closed — the FDA determined that clinical need for 503B bulk compounding no longer exists.
Safety data has reinforced this. As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide. Many involved dosing errors from multi-dose vials where patients self-administered incorrect amounts. Separately, an Eli Lilly-commissioned study identified chemical impurities in tirzepatide compounded with vitamin B12, which is not an FDA-approved combination.
What this means for patients
If finalized as proposed, the rule would close the door on industrial-scale GLP-1 compounding from 503B facilities. Patients who rely on compounded tirzepatide or semaglutide for cost reasons face a shrinking timeline to transition to brand-name products or other alternatives.
The 503A compounding pathway — which applies to traditional, smaller pharmacies compounding for individual patients with specific medical needs — operates under different rules. The April 30 proposal specifically targets 503B outsourcing facilities. However, the 503A window for GLP-1s had already effectively closed with the shortage list removals.
Industry analysts broadly expect finalization by Q3 2026. The comment period provides an opportunity for pharmacies, patient advocacy groups, and prescribers to submit arguments — but a reversal of the FDA's position is considered unlikely given the shortage resolution.
What to watch
Submit public comments by June 29, 2026 at the FDA's docket. For patients currently on compounded GLP-1s, the practical question is what happens to cost and access once the final rule takes effect. Our compounded semaglutide guide and tirzepatide access overview have background on the landscape.
Sources
Sources